The research, which appears in the Journal of the National Comprehensive Cancer Network, uncovered trends in cancer funding that highlight areas needing more attention.

The funding of certain types of cancer was poor, considering how often they occur and how many people die from them. These types included colon, endometrial, liver and bile duct, cervical, ovarian, pancreatic, and lung cancer.

On the other hand, some cancers — including breast and pediatric cancer, leukemia, and lymphoma — received significantly more funding relative to those factors.

The lead researchers, all from Northwestern University in Evanston, IL, were: Suneel Kamath, the chief fellow in the department of hematology and oncology at the university's Feinberg School of Medicine at the time of this study; Sheetal Kircher, assistant professor of hematology and oncology at Feinberg; and Al Benson, professor of hematology and oncology at Feinberg.

"Well-funded patient advocacy organizations should be applauded for their successes," says Kircher. "We hope to bring awareness to the organizations with less relative funding so we can collaborate to improve funding and outcomes for all patients with cancer."

IRS tax records reveal funding disparities

To uncover how much funding each type of cancer received, the researchers looked at the IRS tax records for nonprofits that raise money for any type of cancer. They only included organizations that reported at least $5 million in annual revenue in 2015.

Overall, there were 119 nonprofit organizations, and together, they raised $5.98 billion in annual revenue. A large chunk of this amount was not for one specific cancer — instead, the money went to general cancer funds, such as the American Cancer Society.

http://www.gzjiayumed.com/en/index.asp